title: Stent choice and the hidden consequences of cost savings.
abstract: Amin and colleagues have attempted to estimate the cost savings to the US health-care system if drug-eluting coronary stents were more selectively used in patients at low risk of restenosis. Their results and conclusions raise statistical, societal, and ethical issues that need to be considered before this approach should be widely embraced.
authors.affiliation: TIMI Study Group, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
authors.forename: Matthew A
authors.initials: MA
authors.lastname: Cavender
authors.forename: Stephen G
authors.initials: SG
authors.lastname: Ellis
mesh_terms: D023903:Coronary Restenosis / Q000191:economics* / Q000517:prevention & control; D017046:Cost Savings / Q000191:economics* / Q000706:statistics & numerical data; D054855:Drug-Eluting Stents / Q000191:economics* / Q000706:statistics & numerical data; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000191:economics / Q000627:therapeutic use; D018570:Risk Assessment; D014481:United States
chemical_list: D010975:Platelet Aggregation Inhibitors